Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B. Bitzer M, et al. Among authors: mais a. J Hepatol. 2016 Aug;65(2):280-8. doi: 10.1016/j.jhep.2016.02.043. Epub 2016 Mar 4. J Hepatol. 2016. PMID: 26952006 Clinical Trial.
First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
Brunetto AT, Ang JE, Lal R, Olmos D, Molife LR, Kristeleit R, Parker A, Casamayor I, Olaleye M, Mais A, Hauns B, Strobel V, Hentsch B, de Bono JS. Brunetto AT, et al. Among authors: mais a. Clin Cancer Res. 2013 Oct 1;19(19):5494-504. doi: 10.1158/1078-0432.CCR-13-0735. Epub 2013 Sep 24. Clin Cancer Res. 2013. PMID: 24065624 Free PMC article. Clinical Trial.
Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera.
Eliadis P, Mais A, Papazisis A, Loxa EK, Dimitriadis A, Sarrigeorgiou I, Backovic M, Agallou M, Zouridakis M, Karagouni E, Lazaridis K, Mamalaki A, Lymberi P. Eliadis P, et al. Among authors: mais a. Vaccines (Basel). 2024 Aug 13;12(8):914. doi: 10.3390/vaccines12080914. Vaccines (Basel). 2024. PMID: 39204038 Free PMC article.
Progress, applications, and challenges in high-throughput effect-directed analysis for toxicity driver identification - is it time for HT-EDA?
Alvarez-Mora I, Arturi K, Béen F, Buchinger S, El Mais AER, Gallampois C, Hahn M, Hollender J, Houtman C, Johann S, Krauss M, Lamoree M, Margalef M, Massei R, Brack W, Muz M. Alvarez-Mora I, et al. Among authors: el mais aer. Anal Bioanal Chem. 2024 Jul 12. doi: 10.1007/s00216-024-05424-4. Online ahead of print. Anal Bioanal Chem. 2024. PMID: 38992177 Review.
TFEB signaling attenuates NLRP3-driven inflammatory responses in severe asthma.
Theofani E, Semitekolou M, Samitas K, Mais A, Galani IE, Triantafyllia V, Lama J, Morianos I, Stavropoulos A, Jeong SJ, Andreakos E, Razani B, Rovina N, Xanthou G. Theofani E, et al. Among authors: mais a. Allergy. 2022 Jul;77(7):2131-2146. doi: 10.1111/all.15221. Epub 2022 Jan 25. Allergy. 2022. PMID: 35038351
[Unplanned pregnancy-now what? : Effectiveness and acceptance of medical teaching units for primary and secondary prevention in schools].
Paetzel B, Isensee B, Kramer H, Mais A, Klapp C. Paetzel B, et al. Among authors: mais a. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 Nov;64(11):1398-1407. doi: 10.1007/s00103-021-03423-9. Epub 2021 Sep 22. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021. PMID: 34550413 Clinical Trial. German.
15 results